PMID- 23627026
OWN - NLM
STAT- MEDLINE
DCOM- 20130628
LR  - 20130430
IS  - 1003-9279 (Print)
IS  - 1003-9279 (Linking)
VI  - 26
IP  - 6
DP  - 2012 Dec
TI  - [Effect of kurarinol on peripheral blood CTL surface PD-1 expression of patients 
      with chronic hepatitis B].
PG  - 446-9
AB  - OBJECTIVE: To explore the anti-viral mechanism of kurarinol through studying its 
      influence on cytotoxic T lymphocyte (CTL) surface program death receptor-1 (PD-1) 
      expression of patients with chronic hepatitis B (CHB). METHODS: 69 cases of CHB, 
      HBV DNA > or = 10(4) copies/ml, HBeAg positive, human leukocyte antigen (HLA)-A2 
      positive, alanine aminotransferase (ALT) > 2 x upper limit of normal 
      value(ULN).69 cases were randomly divided into two groups:34 cases in treatment 
      group,600 mg of kurarinol glucose injection was used for intravenous dripping, 
      once a day, one month later, 200 mg of kurarinol capsule was used orally,three 
      times a day and 200 mg of silybin meglumine tablet was used orally, three times a 
      day. 35 cases in control group, only silibin meglumine tablet was used, method 
      and dosage were the same as those of treatment group. Three months later, their 
      peripheral blood HBV specific CTL surface PD-1 expression, non-specific CTL 
      surface PD-1 expression and level of HBV specific CTL,HBV DNA and HBeAg negative 
      rate and liver functions were analyzed and compared. RESULTS: 3 months after 
      treatment, peripheral blood HBV specific CTL surface PD-1 expression of the 
      treatment group decreased compared with that before treatment (t = 2.39, P < 
      0.05), it also decreased compared with that of the control group 3 months after 
      treatment (t = 2.26, P < 0.05), HBV specific CTL increased compared with that 
      before treatment( t = 3.01, P < 0.01), it also increased compared with that of 
      the control group after treatment (t = 2.65, P < 0.05). There was no significant 
      difference of non-specific CTL surface PD-1 expression compared with that before 
      treatment (P > 0.05), and there was no significant difference compared with that 
      of the control group after treatment (P > 0.05). HBV DNA of 11 cases (32.5%) 
      turned negative ( HBV DNA < 500 copies/ ml), higher than that of the control 
      group after treatment (2 cases, 5.71%) chi2 = 7.99, P < 0.01, HBeAg of 9 cases 
      (26.47%) turned negative, higher than that of the control group after treatment 
      (1 case, 2.86%), chi2 = 7.75, P < 0.01. CONCLUSION: Kurarinol can increase level 
      of HBV specific CTL by down-regulating peripheral blood HBV specific CTL surface 
      PD-1 expression of CHB patients, which may be one of the possible mechanisms that 
      kurarinol can remove or inhibit HBV of CHB patients.
FAU - Zhu, Yin-Fang
AU  - Zhu YF
AD  - Wuxi Hospital for Infectious Diseases, China.
FAU - Gu, Xi-Bing
AU  - Gu XB
FAU - Yang, Xiao-Juan
AU  - Yang XJ
FAU - Hua, Zhong
AU  - Hua Z
FAU - Lu, Zhong-Hua
AU  - Lu ZH
FAU - Zang, Bo
AU  - Zang B
FAU - Wu, Hang-Yuan
AU  - Wu HY
FAU - Jiang, Yi-Ming
AU  - Jiang YM
FAU - Chen, Hao-Kun
AU  - Chen HK
FAU - Pei, Hao
AU  - Pei H
FAU - Xu, Yue-Qin
AU  - Xu YQ
LA  - chi
PT  - English Abstract
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi
JT  - Zhonghua shi yan he lin chuang bing du xue za zhi = Zhonghua shiyan he linchuang 
      bingduxue zazhi = Chinese journal of experimental and clinical virology
JID - 9602873
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (Flavonoids)
RN  - 0 (PDCD1 protein, human)
RN  - 0 (Programmed Cell Death 1 Receptor)
RN  - 0 (kurarinol)
SB  - IM
MH  - Adult
MH  - Drugs, Chinese Herbal/*administration & dosage
MH  - Flavonoids/*administration & dosage
MH  - Gene Expression/*drug effects
MH  - Hepatitis B virus/physiology
MH  - Hepatitis B, Chronic/*drug therapy/*genetics/immunology/virology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Programmed Cell Death 1 Receptor/*genetics/immunology
MH  - T-Lymphocytes, Cytotoxic/*drug effects/*immunology
MH  - Treatment Outcome
MH  - Young Adult
EDAT- 2013/05/01 06:00
MHDA- 2013/07/03 06:00
CRDT- 2013/05/01 06:00
PHST- 2013/05/01 06:00 [entrez]
PHST- 2013/05/01 06:00 [pubmed]
PHST- 2013/07/03 06:00 [medline]
PST - ppublish
SO  - Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2012 Dec;26(6):446-9.